{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:10:22Z","timestamp":1794964222437,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"8103","license":[{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T00:00:00Z","timestamp":1767744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,2,26]]},"DOI":"10.1038\/s41586-025-09906-y","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T16:01:48Z","timestamp":1767801708000},"page":"961-969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Oral 4\u2032-fluorouridine rescues nonhuman primates from advanced Lassa fever"],"prefix":"10.1038","volume":"650","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7718-1522","authenticated-orcid":false,"given":"Robert W.","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7669-223X","authenticated-orcid":false,"given":"Jacquelyn","family":"Turcinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-2077","authenticated-orcid":false,"given":"Abhishek N.","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriya","family":"Borisevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7319-6935","authenticated-orcid":false,"given":"Krystle N.","family":"Agans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Deer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"O\u2019Toole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie S.","family":"Dobias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3389-0137","authenticated-orcid":false,"given":"Courtney","family":"Woolsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla A.","family":"Fenton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0858-1877","authenticated-orcid":false,"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"9906_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41579-022-00789-8","volume":"21","author":"RF Garry","year":"2023","unstructured":"Garry, R. F. Lassa fever \u2014 the road ahead. Nat. Rev. Microbiol. 21, 87\u201396 (2023).","journal-title":"Nat. Rev. Microbiol."},{"key":"9906_CR2","doi-asserted-by":"crossref","unstructured":"Grant, D. S., Samuels, R. J., Garry, R. F. & Schieffelin, J. S. in Lassa Fever: Epidemiology, Immunology, Diagnostics, and Therapeutics Current Topics in Microbiology and Immunology (ed. Garry, R.) 165\u2013192 (Springer, 2023).","DOI":"10.1007\/82_2023_263"},{"key":"9906_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ado7034","volume":"16","author":"SR Welch","year":"2024","unstructured":"Welch, S. R. et al. Delayed low-dose oral administration of 4\u2032-fluorouridine inhibits pathogenic arenaviruses in animal models of lethal disease. Sci. Transl. Med. 16, eado7034 (2024).","journal-title":"Sci. Transl. Med."},{"key":"9906_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa035","volume":"27","author":"T Wolf","year":"2020","unstructured":"Wolf, T., Ellwanger, R., Goetsch, U., Wetzstein, N. & Gottschalk, R. Fifty years of imported Lassa fever: a systematic review of primary and secondary cases. J. Travel Med. 27, taaa035 (2020).","journal-title":"J. Travel Med."},{"key":"9906_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.15585\/mmwr.mm7411a3","volume":"74","author":"DL Von Stein","year":"2025","unstructured":"Von Stein, D. L. et al. Notes from the field: response to a case of travel-associated Lassa Fever \u2014 Iowa, October\u2013November 2024. Morb. Mortal. Weekly Rep. 74, 194\u2013196 (2025).","journal-title":"Morb. Mortal. Weekly Rep."},{"key":"9906_CR6","doi-asserted-by":"publisher","first-page":"r492","DOI":"10.1136\/bmj.r492","volume":"388","author":"J Wise","year":"2025","unstructured":"Wise, J. UK authorities are \u201cworking at speed\u201d to trace contacts of Lassa fever case. BMJ 388, r492 (2025).","journal-title":"BMJ"},{"key":"9906_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33112-3","volume":"13","author":"R Klitting","year":"2022","unstructured":"Klitting, R. et al. Predicting the evolution of the Lassa virus endemic area and population at risk over the next decades. Nat. Commun. 13, 5596 (2022).","journal-title":"Nat. Commun."},{"key":"9906_CR8","unstructured":"2018 Annual Review of Diseases Prioritized Under the Research and Development Blueprint (World Health Organization, 2018)."},{"key":"9906_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. New Engl. J. Med. 314, 20\u201326 (1986).","journal-title":"New Engl. J. Med."},{"key":"9906_CR10","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3201\/eid2808.211787","volume":"28","author":"H-Y Cheng","year":"2022","unstructured":"Cheng, H.-Y. et al. Lack of Evidence for Ribavirin Treatment of Lassa Fever in Systematic Review of Published and Unpublished Studies. Emerging Infectious Disease journal 28, 1559 (2022).","journal-title":"Emerging Infectious Disease journal"},{"key":"9906_CR11","doi-asserted-by":"publisher","first-page":"e0010289","DOI":"10.1371\/journal.pntd.0010289","volume":"16","author":"AP Salam","year":"2022","unstructured":"Salam, A. P. et al. Ribavirin for treating Lassa fever: a systematic review of pre-clinical studies and implications for human dosing. PLoS Negl. Trop. Dis. 16, e0010289 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"9906_CR12","unstructured":"FDA-Approved Drugs - REBETOL. US Food and Drug Administration https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/020903s052,021546s008lbl.pdf (2013)."},{"key":"9906_CR13","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/microorganisms9040772","volume":"9","author":"F Hansen","year":"2021","unstructured":"Hansen, F., Jarvis, M. A., Feldmann, H. & Rosenke, K. Lassa virus treatment options. Microorganisms 9, 772 (2021).","journal-title":"Microorganisms"},{"key":"9906_CR14","doi-asserted-by":"publisher","first-page":"e696","DOI":"10.1016\/S1473-3099(24)00229-9","volume":"24","author":"KA Moore","year":"2024","unstructured":"Moore, K. A. et al. Lassa fever research priorities: towards effective medical countermeasures by the end of the decade. Lancet Infect. Dis. 24, e696\u2013e706 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"9906_CR15","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s12985-024-02585-7","volume":"21","author":"BM Warner","year":"2024","unstructured":"Warner, B. M., Safronetz, D. & Stein, D. R. Current perspectives on vaccines and therapeutics for Lassa Fever. Virol. J. 21, 320 (2024).","journal-title":"Virol. J."},{"key":"9906_CR16","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1371\/journal.pmed.0020183","volume":"2","author":"TW Geisbert","year":"2005","unstructured":"Geisbert, T. W. et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med. 2, e183 (2005).","journal-title":"PLoS Med."},{"key":"9906_CR17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw3163","volume":"11","author":"M Mateo","year":"2019","unstructured":"Mateo, M. et al. Vaccines inducing immunity to Lassa virus glycoprotein and nucleoprotein protect macaques after a single shot. Sci. Transl. Med. 11, eaaw3163 (2019).","journal-title":"Sci. Transl. Med."},{"key":"9906_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1172\/JCI131958","volume":"130","author":"RW Cross","year":"2020","unstructured":"Cross, R. W. et al. Quadrivalent VesiculoVax vaccine protects nonhuman primates from viral-induced hemorrhagic fever and death. J. Clin. Invest. 130, 539\u2013551 (2020).","journal-title":"J. Clin. Invest."},{"key":"9906_CR19","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf6348","volume":"13","author":"M Mateo","year":"2021","unstructured":"Mateo, M. et al. A single-shot Lassa vaccine induces long-term immunity and protects cynomolgus monkeys against heterologous strains. Sci. Transl. Med. 13, eabf6348 (2021).","journal-title":"Sci. Transl. Med."},{"key":"9906_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111094","volume":"40","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever. Cell Rep. 40, 111094 (2022).","journal-title":"Cell Rep."},{"key":"9906_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37050-6","volume":"14","author":"M Mateo","year":"2023","unstructured":"Mateo, M. et al. Rapid protection induced by a single-shot Lassa vaccine in male cynomolgus monkeys. Nat. Commun. 14, 1352 (2023).","journal-title":"Nat. Commun."},{"key":"9906_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105647","volume":"114","author":"CL Cooper","year":"2025","unstructured":"Cooper, C. L. et al. Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials. eBioMedicine 114, 105647 (2025).","journal-title":"eBioMedicine"},{"key":"9906_CR23","unstructured":"Ramsauer, K., Lokossou, V. & Oyebanji, O. Bringing together all the pieces of the Lassa fever vaccine puzzle. CEPI https:\/\/cepi.net\/bringing-together-all-pieces-lassa-fever-vaccine-puzzle (2025)."},{"key":"9906_CR24","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3201\/eid2409.180233","volume":"24","author":"K Rosenke","year":"2018","unstructured":"Rosenke, K. et al. Use of favipiravir to treat Lassa virus infection in macaques. Emerg Infect Dis 24, 1696\u20131699 (2018).","journal-title":"Emerg Infect Dis"},{"key":"9906_CR25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2023-EDC.44","author":"G Mirjam","year":"2023","unstructured":"Mirjam, G. OA-652 Safety and tolerability of favipiravir for the treatment of Lassa fever: a randomized controlled open label phase II clinical trial. BMJ Glob. Health https:\/\/doi.org\/10.1136\/bmjgh-2023-EDC.44 (2023).","journal-title":"BMJ Glob. Health"},{"key":"9906_CR26","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/nm.4396","volume":"23","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146\u20131149 (2017).","journal-title":"Nat. Med."},{"key":"9906_CR27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2304876120","volume":"120","author":"RW Cross","year":"2023","unstructured":"Cross, R. W. et al. A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus. Proc. Natl Acad. Sci. USA 120, e2304876120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9906_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101392","volume":"5","author":"RW Cross","year":"2024","unstructured":"Cross, R. W. et al. Monoclonal antibody therapy protects nonhuman primates against mucosal exposure to Lassa virus. Cell Rep. Med. 5, 101392 (2024).","journal-title":"Cell Rep. Med."},{"key":"9906_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2023.2301061","volume":"13","author":"C Woolsey","year":"2024","unstructured":"Woolsey, C. et al. Monoclonal antibody therapy demonstrates increased virulence of a lineage VII strain of Lassa virus in nonhuman primates. Emerg. Microbes Infect. 13, 2301061 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"9906_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adw0659","volume":"11","author":"C Woolsey","year":"2025","unstructured":"Woolsey, C. et al. The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection. Sci. Adv. 11, eadw0659 (2025).","journal-title":"Sci. Adv."},{"key":"9906_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/science.adk6176","volume":"383","author":"RW Cross","year":"2024","unstructured":"Cross, R. W. et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science 383, eadk6176 (2024).","journal-title":"Science"},{"key":"9906_CR32","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/s41591-025-03496-y","volume":"31","author":"RW Cross","year":"2025","unstructured":"Cross, R. W. et al. Oral obeldesivir provides postexposure protection against Marburg virus in nonhuman primates. Nat. Med. 31, 1303\u20131311 (2025).","journal-title":"Nat. Med."},{"key":"9906_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.abj5508","volume":"375","author":"J Sourimant","year":"2022","unstructured":"Sourimant, J. et al. 4\u2032-Fluorouridine is an oral antiviral that blocks respiratory syncytial virus and SARS-CoV-2 replication. Science 375, 161\u2013167 (2022).","journal-title":"Science"},{"key":"9906_CR34","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1089\/dna.2022.0312","volume":"41","author":"CM Lieber","year":"2022","unstructured":"Lieber, C. M. & Plemper, R. K. 4\u2032-Fluorouridine is a broad-spectrum orally available first-line antiviral that may improve pandemic preparedness. DNA Cell Biol. 41, 699\u2013704 (2022).","journal-title":"DNA Cell Biol."},{"key":"9906_CR35","doi-asserted-by":"publisher","first-page":"e1011342","DOI":"10.1371\/journal.ppat.1011342","volume":"19","author":"CM Lieber","year":"2023","unstructured":"Lieber, C. M. et al. 4\u2032-Fluorouridine mitigates lethal infection with pandemic human and highly pathogenic avian influenza viruses. PLoS Path. 19, e1011342 (2023).","journal-title":"PLoS Path."},{"key":"9906_CR36","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422X-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virol. J. 8, 205 (2011).","journal-title":"Virol. J."},{"key":"9906_CR37","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.coviro.2019.07.005","volume":"37","author":"T-L Tang-Huau","year":"2019","unstructured":"Tang-Huau, T.-L., Feldmann, H. & Rosenke, K. Animal models for Lassa virus infection. Curr. Opin. Virol. 37, 112\u2013117 (2019).","journal-title":"Curr. Opin. Virol."},{"key":"9906_CR38","doi-asserted-by":"publisher","first-page":"S359","DOI":"10.1093\/infdis\/jiac266","volume":"228","author":"KM Hastie","year":"2023","unstructured":"Hastie, K. M. et al. The Arenaviridae family: knowledge gaps, animal models, countermeasures, and prototype pathogens. J. Infect. Dis. 228, S359\u2013S375 (2023).","journal-title":"J. Infect. Dis."},{"key":"9906_CR39","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1080\/21505594.2022.2060170","volume":"13","author":"M Mateo","year":"2022","unstructured":"Mateo, M. et al. Pathogenesis of recent Lassa virus isolates from lineages II and VII in cynomolgus monkeys. Virulence 13, 654\u2013669 (2022).","journal-title":"Virulence"},{"key":"9906_CR40","doi-asserted-by":"publisher","first-page":"102263","DOI":"10.1016\/j.xcrm.2025.102263","volume":"6","author":"RW Cross","year":"2025","unstructured":"Cross, R. W. et al. Lassa fever in African green monkeys: clinical disease and fatal outcome are associated with systemic viral dissemination and inflammation. Cell Rep. Med. 6, 102263 (2025).","journal-title":"Cell Rep. Med."},{"key":"9906_CR41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s42003-020-01543-7","volume":"4","author":"N Baillet","year":"2021","unstructured":"Baillet, N. et al. Systemic viral spreading and defective host responses are associated with fatal Lassa fever in macaques. Commun. Biol. 4, 27 (2021).","journal-title":"Commun. Biol."},{"key":"9906_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.it.2019.03.001","volume":"40","author":"CL Scott","year":"2019","unstructured":"Scott, C. L. & Omilusik, K. D. ZEBs: novel players in immune cell development and function. Trends Immunol. 40, 431\u2013446 (2019).","journal-title":"Trends Immunol."},{"key":"9906_CR43","unstructured":"An update of Lassa fever outbreak in Nigeria. Nigeria Centre for Disease Control and Prevention https:\/\/ncdc.gov.ng\/diseases\/sitreps\/?cat=5&name=AnupdateofLassafeveroutbreakinNigeria (2025)."},{"key":"9906_CR44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijid.2022.04.004","volume":"119","author":"V Raabe","year":"2022","unstructured":"Raabe, V. et al. Lassa virus infection: a summary for clinicians. Int. J. Infect. Dis. 119, 187\u2013200 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"9906_CR45","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1128\/JVI.74.5.2186-2192.2000","volume":"74","author":"J ter Meulen","year":"2000","unstructured":"ter Meulen, J. et al. Characterization of human CD4+ T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J. Virol. 74, 2186\u20132192 (2000).","journal-title":"J. Virol."},{"key":"9906_CR46","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1128\/JVI.01948-08","volume":"83","author":"S Baize","year":"2009","unstructured":"Baize, S. et al. Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys. J. Virol. 83, 5890\u20135903 (2009).","journal-title":"J. Virol."},{"key":"9906_CR47","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/0035-9203(85)90388-8","volume":"79","author":"PB Jahrling","year":"1985","unstructured":"Jahrling, P. B., Frame, J. D., Rhoderick, J. B. & Monson, M. H. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79, 380\u2013384 (1985).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"9906_CR48","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1093\/infdis\/155.3.456","volume":"155","author":"KM Johnson","year":"1987","unstructured":"Johnson, K. M. et al. Clinical virology of Lassa fever in hospitalized patients. J. Infect. Dis. 155, 456\u2013464 (1987).","journal-title":"J. Infect. Dis."},{"key":"9906_CR49","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1093\/infdis\/jix201","volume":"215","author":"AK McElroy","year":"2017","unstructured":"McElroy, A. K. et al. A case of human Lassa virus infection with robust acute T-cell activation and long-term virus-specific T-cell responses. J. Infect. Dis. 215, 1862\u20131872 (2017).","journal-title":"J. Infect. Dis."},{"key":"9906_CR50","doi-asserted-by":"crossref","unstructured":"Prasad, A.N. et al. Remdesivir, mAb114, REGN-EB3, and ZMapp partially rescue nonhuman primates infected with a low passage Kikwit variant of Ebola virus. Nat Commun 16, 3824 (2025).","DOI":"10.1038\/s41467-025-59168-5"},{"key":"9906_CR51","doi-asserted-by":"publisher","first-page":"e3001687","DOI":"10.1371\/journal.pbio.3001687","volume":"20","author":"DE Griffin","year":"2022","unstructured":"Griffin, D. E. Why does viral RNA sometimes persist after recovery from acute infections?\u00a0PLoS Biol. 20, e3001687 (2022).","journal-title":"PLoS Biol."},{"key":"9906_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22132-0","volume":"12","author":"RW Cross","year":"2021","unstructured":"Cross, R. W. et al. Combination therapy protects macaques against advanced Marburg virus disease. Nat. Commun. 12, 1891 (2021).","journal-title":"Nat. Commun."},{"key":"9906_CR53","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159090","volume":"7","author":"RW Cross","year":"2022","unstructured":"Cross, R. W. et al. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease. JCI Insight 7, e159090 (2022).","journal-title":"JCI Insight"},{"key":"9906_CR54","doi-asserted-by":"publisher","first-page":"e1012768","DOI":"10.1371\/journal.ppat.1012768","volume":"20","author":"J Hortion","year":"2024","unstructured":"Hortion, J. et al. Fatal Lassa fever in cynomolgus monkeys is associated with systemic viral dissemination and inflammation. PLoS Pathog. 20, e1012768 (2024).","journal-title":"PLoS Pathog."},{"key":"9906_CR55","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/infdis\/jit004","volume":"207","author":"D Safronetz","year":"2013","unstructured":"Safronetz, D. et al. A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. J. Infect. Dis. 207, 1316\u20131327 (2013).","journal-title":"J. Infect. Dis."},{"key":"9906_CR56","doi-asserted-by":"publisher","first-page":"e1009966","DOI":"10.1371\/journal.ppat.1009966","volume":"17","author":"DR Stein","year":"2021","unstructured":"Stein, D. R. et al. Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates. PLoS Pathog. 17, e1009966 (2021).","journal-title":"PLoS Pathog"},{"key":"9906_CR57","unstructured":"Hinds, W. C. in Aerosol Technology: Properties, Behavior, and Measurement of Airborne Particles 233\u2013259 (John Wiley & Sons, 1999)."},{"key":"9906_CR58","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).","journal-title":"Nucleic Acids Res."},{"key":"9906_CR59","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3201\/eid2403.171905","volume":"24","author":"SLM Whitmer","year":"2018","unstructured":"Whitmer, S. L. M. et al. New lineage of Lassa virus, Togo, 2016. Emerg. Infect. Dis. 24, 599\u2013602 (2018).","journal-title":"Emerg. Infect. Dis."},{"key":"9906_CR60","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2009","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2009).","journal-title":"Bioinformatics"},{"key":"9906_CR61","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1093\/bioinformatics\/btt703","volume":"30","author":"A Kramer","year":"2014","unstructured":"Kramer, A., Green, J., Pollard, J. Jr. & Tugendreich, S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics 30, 523\u2013530 (2014).","journal-title":"Bioinformatics"},{"key":"9906_CR62","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1177\/0300985813485099","volume":"50","author":"KN Gibson-Corley","year":"2013","unstructured":"Gibson-Corley, K. N., Olivier, A. K. & Meyerholz, D. K. Principles for valid histopathologic scoring in research. Vet. Pathol. 50, 1007\u20131015 (2013).","journal-title":"Vet. Pathol."},{"key":"9906_CR63","doi-asserted-by":"publisher","unstructured":"Turcinovic, J. 4\u2032 FIU antiviral rescues AGMs from Lassa fever: Nanostring transcriptomic analyses (v1.0). Zenodo https:\/\/doi.org\/10.5281\/zenodo.15230970 (2025).","DOI":"10.5281\/zenodo.15230970"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09906-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09906-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:09:01Z","timestamp":1772024941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09906-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,7]]},"references-count":63,"journal-issue":{"issue":"8103","published-print":{"date-parts":[[2026,2,26]]}},"alternative-id":["9906"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09906-y","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,7]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}